Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Insights into MRSA Epidemic

Published: Wednesday, May 02, 2012
Last Updated: Wednesday, May 02, 2012
Bookmark and Share
Scientists identify a gene playing a pivotal role in epidemic waves of MRSA infections in Asia.

NIH scientists and their colleagues in China have identified a gene that’s been playing a pivotal role in epidemic waves of methicillin-resistant Staphylococcus aureus (MRSA) infections in Asia. The finding suggests a potential target for novel therapeutics.

Decades ago, doctors used penicillin to treat people infected with the S. aureus bacterium, commonly known as staph. When S. aureus developed resistance to the antibiotic, doctors turned to methicillin.

In 1961, scientists identified the first strains of S. aureus bacteria that resisted methicillin. MRSA is now a leading cause of severe infections in hospitals.

Since bacteria inherit identical copies of their mother cell's genes, lineages are referred to as clones. MRSA epidemics occur in waves, with old clones of MRSA bacteria disappearing and new clones emerging.

A limited number of MRSA clones are responsible for most MRSA infections worldwide.

In China and large parts of Asia, ST239 is the predominant MRSA lineage. Recently, genome sequencing of ST239 revealed a rare new gene.

A research team led by Dr. Michael Otto of NIH's National Institute of Allergy and Infectious Diseases (NIAID) and Dr. Yuan Lu of Fudan University in Shanghai set out to study whether the new gene, which they called sasX, might play a role in the spread of MRSA in China.

The researchers analyzed 807 patient samples of invasive S. aureus taken over the past decade from 3 Chinese hospitals.

In the early online edition of Nature Medicine on April 22, 2012, they reported that sasX is more prevalent in MRSA strains from China than previously thought.

They found that the gene's frequency is also increasing: From 2003 to 2011, the percentage of MRSA samples containing sasX almost doubled, from 21% to 39%.

Most of the sasX-positive samples in the study were from ST239. However, while sasX was found almost exclusively among ST239 strains early in the study, its frequency among other clonal types increased considerably since then, from 5% in 2003-2005 to 28% in 2009-2011.

This supports a long-held theory that new clones of virulent MRSA arise through the exchange of DNA between different strains. Indeed, the sasX gene is embedded in a so-called mobile genetic element, a DNA segment that can transfer easily between strains.

The researchers next explored the biological role of sasX. They found that the protein coded by sasX appears at the S. aureus cell surface.

A series of laboratory and mouse studies showed that sasX helps the bacteria to colonize the nose and cause skin abscesses and lung disease. The protein also helps the bacteria evade human immune defenses.

Taken together, these findings establish sasX as a crucial factor in MRSA's virulence and a probable driving force of the Asian MRSA epidemic. “This research helps us understand how new, more dangerous forms of MRSA can keep appearing,” Otto says.

Based on their observations, the researchers predict that sasX is likely to continue to spread. They plan to keep monitoring its progress. They're also working to develop therapeutics against MRSA strains that express sasX.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.
Tuesday, November 10, 2015
NIH Announces High-Risk, High-Reward Research Awardees
NIH to fund 78 awards to support highly innovative biomedical research.
Wednesday, October 07, 2015
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Thursday, August 27, 2015
Large Percentage of Youth with HIV May Lack Immunity to Measles, Mumps, Rubella
NIH study finds those vaccinated before starting modern HIV therapy may be at risk.
Tuesday, August 18, 2015
NIH-funded Vaccine for West Nile Virus Enters Human Clinical Trials
Enrollment is expected to be completed by December 2015.
Tuesday, July 07, 2015
Douglas Lowy Named Acting Director of the National Cancer Institute
Lowy’s research includes the biology of papillomaviruses and the regulation of normal and neoplastic growth.
Tuesday, April 07, 2015
Experimental Ebola Vaccine Safe, Prompts Immune Response
Results from US government-sponsored phase 1 trial of VSV vaccine reported.
Thursday, April 02, 2015
Ebola Test Vaccines Appear Safe in Phase 2 Liberian Clinical Trial
Liberia-U.S. partnership planning Phase 3 trial and study of Ebola survivors.
Friday, March 27, 2015
Strengthening the Immune System’s Fight Against Brain Cancer
NIH-funded research suggests novel way to improve vaccine efficacy in brain tumors.
Friday, March 20, 2015
NIH-Sponsored HIV Vaccine Trial Launches In South Africa
Early-stage trial aims to build on RV144 results.
Thursday, February 19, 2015
Ebola Vaccine Trial Opens in Liberia
Study led by Liberia-NIH partnership will test two experimental vaccines.
Tuesday, February 03, 2015
NIAID/GSK Experimental Ebola Vaccine Appears Safe, Prompts Immune Response
Results from NIH Phase 1 clinical trial support accelerated development of candidate vaccine.
Friday, November 28, 2014
NIH Begins Early Human Clinical Trial of VSV Ebola Vaccine
Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health’s Clinical Center in Bethesda, Maryland.
Thursday, October 23, 2014
Candidate H7N9 Avian Flu Vaccine Works Better With Adjuvant
Results of large NIH-sponsored trial demonstrate improved vaccine response when an adjuvant was used.
Wednesday, October 08, 2014
NIH Awards Seven New Vaccine Adjuvant Discovery Contracts
Total funding for these contracts reach approximately $70 million over five years.
Tuesday, October 07, 2014
Scientific News
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos